Personalized Accelerated ChEmoRadiation (PACER) for Lung Cancer

Launched by STANFORD UNIVERSITY · Oct 6, 2023

Keywords

ClinConnect Summary

The PACER trial is a clinical study looking at a new way to treat locally advanced lung cancer using a type of radiation therapy called hypofractionated accelerated radiation therapy (HART). This method delivers radiation in fewer, larger doses, which may help improve treatment effectiveness. The trial is currently recruiting participants who are between the ages of 18 and 74 and have been diagnosed with lung cancer, either non-small cell or small cell. To be eligible, participants should have a good performance status, meaning they can carry out daily activities, and must expect to live for at least 12 weeks.

If you join the trial, you will receive a combination of radiation therapy and other treatments as part of your care. Before participating, you will need to sign a consent form, ensuring you understand the study and agree to participate. It’s important to note that certain conditions, such as previous radiation to the chest or specific lung diseases, may prevent someone from joining the trial. Overall, this study aims to explore a personalized approach to treating lung cancer, potentially leading to better outcomes for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Histologically or cytologically documented malignancy of the lung including non-small cell lung cancer or small cell lung cancer planned for definitive therapy with fractionated radiation (60-66 Gy) and concurrent systemic therapy
• • ECOG performance status of 0-2
• • Age \> 18 years old
• • Ability to understand and the willingness to personally sign the written IRB approved informed consent document
• • Estimated life expectancy of 12 weeks or longer
• Exclusion Criteria:
• • Contraindication to receiving radiotherapy or systemic therapy as determined by treating radiation and medical oncologist
• • Age \< 18 years old
• • Tumor directly invading the major pulmonary arteries, aorta, heart or proximal bronchial tree
• • Diagnosis of interstitial pulmonary fibrosis
• • Previous radiation therapy to the thorax that would result in overlapping high dose radiation fields